MoonLake Immunotherapeutics’s recent filing unveils that its Chief Executive Officer Santos da Silva Jorge unloaded Company’s shares for reported $1.96 million on Dec 08 ’25. In the deal valued at $15.08 per share,130,000 shares were sold. As a result of this transaction, Santos da Silva Jorge now holds 2,948,577 shares worth roughly $43.61 million.
Then, Santos da Silva Jorge sold 70,000 shares, generating $1,014,300 in total proceeds. Upon selling the shares at $14.49, the Chief Executive Officer now owns 2,878,577 shares.
Before that, Reich Kristian sold 130,000 shares. MoonLake Immunotherapeutics shares valued at $1,960,400 were divested by the Chief Scientific Officer at a price of $15.08 per share. As a result of the transaction, Reich Kristian now holds 72,908 shares, worth roughly $1.08 million.
H.C. Wainwright upgraded its MoonLake Immunotherapeutics [MLTX] rating to a Buy from a a Neutral in a research note published recently. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who decreased its forecast for the stock in early October from “a Buy” to “a Neutral”. Goldman also remained covering MLTX and has decreased its forecast on October 01, 2025 with a “Neutral” recommendation from previously “Buy” rating. Wolfe Research revised its rating on September 30, 2025. It rated MLTX as “an Underperform” which previously was an “an Outperform”.
Price Performance Review of MLTX
On Friday, MoonLake Immunotherapeutics [NASDAQ:MLTX] saw its stock jump 5.12% to $14.79. Over the last five days, the stock has lost -0.74%. MoonLake Immunotherapeutics shares have fallen nearly -72.53% since the year began. Nevertheless, the stocks have fallen -72.69% over the past one year. While a 52-week high of $62.75 was reached on 09/26/25, a 52-week low of $5.95 was recorded on 09/29/25.
Levels Of Support And Resistance For MLTX Stock
The 24-hour chart illustrates a support level at 14.27, which if violated will result in even more drops to 13.74. On the upside, there is a resistance level at 15.15. A further resistance level may holdings at 15.50.
How much short interest is there in MoonLake Immunotherapeutics?
A steep rise in short interest was recorded in MoonLake Immunotherapeutics stocks on 2025-11-28, dropping by -0.64 million shares to a total of 4.27 million shares. Yahoo Finance data shows the prior-month short interest on 2025-10-31 was 4.91 million shares. There was a decline of -14.93%, which implies that there is a negative sentiment for the stock.
